Compounds > 22-hydroxyacuminatine
Page last updated: 2024-11-11

22-hydroxyacuminatine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

22-hydroxyacuminatine: cytotoxic; isolated from Camptotheca acuminata; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
CamptothecagenusA plant genus of the family NYSSACEAE (sometimes classified in the CORNACEAE family). It is a source of CAMPTOTHECIN.[MeSH]NyssaceaeThe sour gum family of the order Cornales.[MeSH]

Cross-References

ID SourceID
PubMed CID9883320
CHEMBL ID205175
MeSH IDM0496362

Synonyms (3)

Synonym
22-hydroxyacuminatine
CHEMBL205175
19-(hydroxymethyl)-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15,17,19-nonaen-14-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID321563Antiproliferative activity against human HT29 cells at 2 uM after 96 hrs2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Synthesis and bioevaluation of 22-hydroxyacuminatine analogs.
AID321561Antiproliferative activity against human DU145 cells at 2 uM after 96 hrs2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Synthesis and bioevaluation of 22-hydroxyacuminatine analogs.
AID366208Inhibition of human recombinant topoisomerase 1 assessed as DNA cleavage relative to 1 uM camptothecin2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.
AID321556Cytotoxicity against mouse P388 cells2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Synthesis and bioevaluation of 22-hydroxyacuminatine analogs.
AID260511Cytotoxicity against P388 murine leukemic cell line2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Total synthesis and biological evaluation of 22-hydroxyacuminatine.
AID321557Cytotoxicity against human KB cells2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Synthesis and bioevaluation of 22-hydroxyacuminatine analogs.
AID321559Antiproliferative activity against human MIA PaCa cells after 96 hrs2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Synthesis and bioevaluation of 22-hydroxyacuminatine analogs.
AID260512Cytotoxicity against topoisomerase 1-deficient subclone P388/CPT45 murine leukemic cell line2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Total synthesis and biological evaluation of 22-hydroxyacuminatine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.0310pyrrole;
secondary amine
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.4420delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
sn 38
SN-38 : A member of the class of pyranoindolizinoquinolines that is (4S)-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione bearing two additional ethyl substituents at positions 4 and 11 as well as two additional hydroxy substituents at positions 4 and 9. It is the active metabolite of irinotecan and is ~1000 times more active than irinotecan itself.		2.0410delta-lactone;
phenols;
pyranoindolizinoquinoline;
tertiary alcohol		antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
nsc 314622
NSC 314622: structure in first source		2.0410
nsc 706744
[no description available]		2.0410
luotonin a
luotonin A: structure in first source		7.0310quinazolines
rosettacin
rosettacin: structure in first source		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.0410
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0410